Year: 2025
Type: article
Study design: Case Report
Abstract: Background: Denosumab has emerged as an effective therapy for managing giant cell tumor of the bone (GCT).However, its use is limited by the osteonecrosis of the jaw (ONJ).Case presentation: We describe a Caucasian woman with GCT of the 3 rd middle phalange who developed ONJ after several years of denosumab therapy requiring cessation of treatment.As an alternative to amputation, intra-tumoral denosumab provided durable and complete tumour regression without causing recurrence of ONJ.Conclusion: Intra-tumoral administration of denosumab constitutes an effective and durable method of drug delivery and should be considered for patients or who develop ONJ while receiving denosumab or whose dentition places them at high risk of ONJ.
Authors: Michael P Castro, Erlinda M Gordon, Sant Chawla
Institutions: Beverly Hills Cancer Center, Sarcoma Oncology Center
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4409591043